SeQuent Scientific, backed by Carlyle, and Viyash Life Sciences announced a ₹8,000 crore merger, creating one of India’s largest animal health companies. The combined entity will have 16 manufacturing facilities and access to over 150 global markets. SeQuent focuses on animal health, while Viyash makes human pharmaceutical ingredients. The merger will expand SeQuent's capital base from 240 million to 428 million shares. SeQuent's shares rose 14%, closing at ₹217.35, valuing the company at ₹9,323 crore. In FY24, SeQuent reported ₹1,369 crore in revenue with a net loss of ₹29.6 crore.